RozR1LALA: Rhesus recombinant, humanized, effector-silenced IgG1-kappa anti-FcRn antibody. Derived from rozanolixizumab.
Effect of a single dose of rhesus anti-FcRn mAb (30mg/kg IV, n=6) on circulating total IgG levels. (A) Total serum IgG concentration for individual animals (left). Total IgG level was reduced after anti-FcRn mAb treatment. PMID 34149698
Because of the mechanism of action of this mAb (blocking IgG recycling), you should expect a reduced half-live for all antibodies during aFcRn therapy (a dose of 10mg is washed out in ~3 days).